Page last updated: 2024-09-04
gl 331 and Neoplasms
gl 331 has been researched along with Neoplasms in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chao, Y; Chen, LL; Chen, LT; Chen, MH; Huang, TS; Lee, CC; Shu, CH; Whang-Peng, J; Yuan, CC | 1 |
Other Studies
1 other study(ies) available for gl 331 and Neoplasms
| Article | Year |
|---|---|
A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Tumor Cells, Cultured | 1999 |